Early Changes in Apparent Diffusion Coefficient as an Indicator of Response to Sorafenib in Hepatocellular Carcinoma

Journal of Zhejiang University: Science B - China
doi 10.1631/jzus.b1400010
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Zhejiang University Press

Related search

Re: Baseline and Early MR Apparent Diffusion Coefficient Quantification as a Predictor of Response of Unresectable Hepatocellular Carcinoma to Doxorubicin Drug-Eluting Bead Chemoembolization

Journal of Vascular and Interventional Radiology
Nuclear MedicineRadiologyCardiologyCardiovascular MedicineImagingMedicine
2016English

Sorafenib in Hepatocellular Carcinoma

Clinical Medicine. Therapeutics
2009English

Analysis of the Early Response to Chemotherapy in Lung Cancer Using Apparent Diffusion Coefficient Single-Slice Histogram

Tropical Journal of Pharmaceutical Research
PharmacologyPharmaceutical Science
2018English

Early Α-Fetoprotein Response Predicts Survival in Patients With Advanced Hepatocellular Carcinoma Treated With Sorafenib

Journal of Hepatocellular Carcinoma
2015English

Early Apparent Diffusion Coefficient Change During Neoadjuvant Chemoradiation Predicts Pathologic and Clinical Response in Esophageal Cancer

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2016English

Cytotoxicity of Sorafenib in Human Hepatocellular Carcinoma Cells

Al-Azhar Journal of Pharmaceutical Sciences
2015English

Sorafenib-Related Adverse Events in Predicting the Early Radiologic Responses of Hepatocellular Carcinoma

Gastroenterology Research
2019English

Application of the Apparent Diffusion Coefficient in Magnetic Resonance Imaging in an Assessment of the Early Response to Treatment in Hodgkin’s and Non-Hodgkin’s Lymphoma – Pilot Study

Polish Journal of Radiology
2018English

Sorafenib vs Nivolumab in Patients With Hepatocellular Carcinoma

Journal of Liver Research, Disorders & Therapy
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy